Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer

被引:24
作者
Nakamoto, Regina Hiromi [1 ]
Uetake, Hiroyuki [1 ]
Iida, Satoru [1 ]
Kolev, Yanislav Velchev [1 ]
Soumaoro, Labile Togba [1 ]
Takagi, Yoko [1 ]
Yasuno, Masamichi [1 ]
Sugihara, Kenichi [1 ]
机构
[1] Tokyo Med & Dent Univ, Dept Surg Oncol, Grad Sch, Bunkyo Ku, Tokyo 1138519, Japan
关键词
primary colorectal cancer; liver metastases; angiogenesis; cyclooxygenase-2;
D O I
10.1093/jjco/hym080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Angiogenesis is required for growth and metastasis of colorectal cancer (CRC), and several positive regulators of tumor angiogenesis have been identified. Cyclooxygenase-2 (COX-2), known to be elevated in several human cancers, regulates angiogenesis by inducing angiogenic factors. The aim of this study was to clarify the levels and evaluate the relationships of COX-2, vascular endothelial growth factor A and C, thymidine phosphorylase (TP) and microvascular density (MVD) in paired tissue specimens between primary CRC and corresponding metastatic liver cancer. Methods: Tissue samples from pairs of primary tumors and corresponding metastatic liver tumors from 44 patients with CRC were immunohistochemically evaluated for COX-2, VEGF-A, VEGF-C, TP and MVD. Results: The primary and corresponding metastatic liver tumors tended to show concordant immunoreactivity for COX-2 (P = 0.005, rs = 0.428), VEGF-A (P = 0.039, rs = 0.314), TP (P = 0.005, rs = 0.422) and MVD (P = 0.046, rs = 0.304) by Spearman rank test. The rate of COX-2 immunoreactivity was higher in liver metastases than in primary tumors (P = 0.002), while the rate of VEGF-A was higher in primary tumors than in liver metastases (P = 0.0004). The incidence of TP immunoreactivity and the level of MVD did not differ between primary and metastatic liver tumors (P = 0.247; P = 0.229). Significant correlations were found between COX-2 immunoreactivity and VEGF-A immunoreactivity in metastatic liver tumors (P = 0.033) as well as in primary tumors (P = 0.008). Conclusion: The positive correlations between COX-2, VEGF-A, TP and MVD in primary CRC and liver metastasis as demonstretaed here will help to predict the angiogenic activity of liver metastasis by analyzing primary tumors, allowing for individualized cancer treatment options.
引用
收藏
页码:679 / 685
页数:7
相关论文
共 54 条
[1]  
Agui T, 2002, ANTICANCER RES, V22, P1769
[2]   Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues [J].
Akagi, K ;
Ikeda, Y ;
Miyazaki, M ;
Abe, T ;
Kinoshita, J ;
Maehara, Y ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :887-891
[3]  
Berney CR, 1998, ANTICANCER RES, V18, P973
[4]   COX-2: A molecular target for colorectal cancer prevention [J].
Brown, JR ;
DuBois, RN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2840-2855
[5]  
Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO
[6]  
2-#
[7]   Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression [J].
Couvelard, A ;
O'Toole, D ;
Turley, H ;
Leek, R ;
Sauvanet, A ;
Degott, C ;
Ruszniewski, P ;
Belghiti, J ;
Harris, AL ;
Gatter, K ;
Pezzella, F .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :94-101
[8]   Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy [J].
Duff, SE ;
Jeziorska, M ;
Rosa, DD ;
Kumar, S ;
Haboubi, N ;
Sherlock, D ;
O'Dwyer, ST ;
Jayson, GC .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) :112-117
[9]   Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression [J].
Elder, DJE ;
Baker, JA ;
Banu, NA ;
Moorghen, M ;
Paraskeva, C .
JOURNAL OF PATHOLOGY, 2002, 198 (04) :428-434
[10]   The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases [J].
Fenwick, SW ;
Toogood, GJ ;
Lodge, JPA ;
Hull, MA .
GASTROENTEROLOGY, 2003, 125 (03) :716-729